Journal of Cardiac Failure

Palliative care should be integrated early in the trajectory of heart disease. Read about racial disparities, equality and timing of palliative care consultations in a large urban healthcare system! ???????????? How can we improve care for our patients? Read more to find out. ??https://bit.ly/3MGinb9

To bridge … or not to bridge? ?? Managing peri-procedure anticoagulation can be challenging in LVAD patients. Read about the KVAD study which explores the use of 4F-PCC for temporary warfarin reversal for invasive procedures in LVAD patients! Check out the accompanying editorials: ?? https://bit.ly/4e0ohzE ?? https://bit.ly/3AZOOyC

??The updated 2024 Heart Failure (HF) Epidemiology and Outcomes Statistics Report is now published in @JCardFail! HF-Stats 2024 provides updates to last year's inaugural report with key data and analysis about the state of HF in the U.S. and around the world. ?? Explore HF-Stats for the latest updates about: ??HF incidence, prevalence and lifetime risk estimates ??HF trends in the US and globally including HF hospitalization and mortality rates ??Disparities in social determinants of health and health inequities ??Current use of guideline-directed medical therapy ??Cost of HF-related treatment, and more! ??https://bit.ly/3zm6gwW

?? Only one out of every ten patients with HF were discharged on an SGLT2i from VA Hospitals from 2019-2022. However, prescription rates increased from 2% to 24% over the same period, with substantial variability across VA hospitals. Read about the factors associated with SGLT2i prescription rates in this month's #JCF issue. ??https://bit.ly/47rVoKf Also, check out the accompanying #PatientFocus article that breaks down this study’s findings for your patients! ??: https://bit.ly/4eoHhb9 Natasha Din - MD, MAS Ankeet S. Bhatt, MD, MBA Paul Heidenreich

?? Feeling lost in dealing with the evolving treatment options for hypertrophic cardiomyopathy? We have you covered with this review in the September issue of JCF! Brush up on medical management, septal-reduction, and the latest with myosin modulators here: https://bit.ly/3Tr7td6

?? Discover the latest HF research in our September issue, focusing on #FunctionNotFailure. Dive into expert findings and stay ahead in the field of cardiac failure. Ready to explore expert research? Follow the link: ??https://lnkd.in/eGVd5sdg

JCF is proud to serve as a platform for the change we wish to see in the world. ?? In that spirit, Dr. Anu Lala joins Dr. Robert J. Mentz as Co-Editors-in-Chief! Read more about their thoughts on JCF's future in the September Editor's Page. ??https://bit.ly/3ZtkGWz

Despite #GDMTworks, your patient with HF is still symptomatic & at high risk for adverse outcomes; now what ??? There is an unmet need to address residual risk in patients with chronic heart failure. With an increasing armamentarium of HF devices, it is imperative to better understand and appropriately implement these therapies. Explore the full range of device-based therapies for #FunctionNotFailure in the latest HFSA Scientific Statement in #JCF! ? Remote monitoring ? Valvular- & structural-based therapies ? Autonomic, EP, and respiratory modulators ? Durable MCS ?? https://bit.ly/47pAL1l

Check out this critical #ESCCongress simultaneous publication from #JCF! The sim-pub, titled "Prevalence and Prognostic Implications of Changes in TR Severity during Acute HF," discusses: ?? Persistent TR groups had higher event rates ?? Significant TR after decongestion might be a target for further treatment ?? Head to the link to read the full article: https://bit.ly/3z1I2Ys

??Our August Issue of #JCF is now available! August's issue covers the latest research on #FunctionNotFailure. Are you ready to investigate expert findings? ?? https://bit.ly/3xrO9Es